GlassScriptPhysician profile
Leila Koleiny
NPI 1942597786
$2,379.64
in general payments reported to CMS, 2019-2025
28 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $119 · 2021: $12.26 · 2022: $259 · 2023: $586 · 2024: $428 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,538.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.42 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $298.00 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $262.79 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $224.49 | 2019-2025 | |
| Lilly USA, LLC | $159.56 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $131.46 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.12 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $101.21 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $75.31 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $70.68 | 2020-2025 | Veozah, Myrbetriq |
| Boston Scientific Corporation | $53.62 | 2025 | General - Pain Management |
| Merck Sharp & Dohme LLC | $52.48 | 2019-2024 | Capvaxive |
| Glaxosmithkline, LLC. | $45.59 | 2019-2023 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $41.19 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.87 | 2023 | Xifaxan |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.56 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $27.96 | 2019-2020 | |
| Amarin Pharma, INC. | $25.39 | 2019 | |
| Eisai INC. | $24.47 | 2019 | |
| Organon LLC | $20.42 | 2025 | Nexplanon |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.96 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $19.48 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.33 | 2022 | |
| Exact Sciences Corporation | $16.45 | 2025 | The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $14.81 | 2023 | Tirosint, Licart |
| Kowa Pharmaceuticals America, INC. | $14.59 | 2025 | Zoryve |
| Shire North American Group INC | $14.27 | 2019 | |
| Vanda Pharmaceuticals INC. | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leila Koleiny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.